Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

RVboost: RNA-seq variants prioritization using a boosting method
Wang, Chen , Davila, Jaime , Baheti, Saurabh , Bhagwate, Aditya , Wang, Xue , Kocher, Jean-Pierre A., Feldman, Andrew L. , Novak, Anne J. , Thompson, E. Aubrey , Asmann, Yan W. , Davila, Jaime I, Bhagwate, Aditya V., Slager, Susan L. , Cerhan, James R. , Feldman, Andrew L , Wang, Chen , Davila, Jaime I

Bioinformatics | August 29, 2014 | Volume: 30 | Issue: 23 | Pages: 3414-3416

10.1093/bioinformatics/btu577 | PMID 25170027 Get It

Abstract Motivation: RNA-seq has become the method of choice to quantify genes and exons, discover novel transcripts and detect fusion genes. However, reliable variant identification from RNA-seq data remains challenging because of the complexities of the transcriptome, the challenges of accurately mapping exon boundary spanning reads and the bias introduced during the sequencing library preparation. Method: We developed RVboost, a novel method specific for RNA variant prioritization. RVboost uses several attributes unique in the process of RNA library preparation, sequencing and RNA-seq data analyses. It uses a boosting method to train a model of ‘good quality’ variants using common variants from HapMap, and prioritizes and calls the RNA variants based on the trained model. We packaged RVboost in a comprehensive workflow, which integrates tools of variant calling, annotation and filtering. Results: RVboost consistently outperforms the variant quality score recalibration from the Genome Analysis Tool Kit and the RNA-seq variant-calling pipeline SNPiR in 12 RNA-seq samples using ground-truth variants from paired exome sequencing data. Several RNA-seq–specific attributes were identified as critical to differentiate true and false variants, including the distance of the variant positions to exon boundaries, and the percent of the reads supporting the variant in the first six base pairs. The latter identifies false variants introduced by the random hexamer priming during the library construction. Availability and implementation: The RVboost package is implemented to readily run in Mac or Linux environments. The software and user manual are available at http://bioinformaticstools.mayo.edu/research/rvboost/. Supplementary information: Supplementary data are available at Bioinformatics online.
Serum Procalcitonin Levels in Patients with Primary Pulmonary Coccidioidomycosis
Sakata, Kenneth K. , Grys, Thomas E. , Vikram, Holenarasipur R. , Blair, Janis E. , Chang, Yu‐Hui , Vikram, Holenarasipur R. , Grys, Thomas E

Annals of the American Thoracic Society | August 28, 2014 | Volume: 11 | Issue: 8 | Pages: 1239-1243

10.1513/annalsats.201404-180bc | PMID 25168059 Get It

Abstract Rationale The serum procalcitonin assay has emerged as a promising biomarker to distinguish between bacterial and viral respiratory tract infections but has not been used to differentiate coccidioidomycosis from bacterial infection. A correlation between procalcitonin serum levels and coccidioidomycosis has never been reported. Objective To determine any association between serum procalcitonin levels and primary pulmonary coccidioidomycosis. Methods We identified and enrolled 20 immunocompetent patients with symptomatic primary pulmonary coccidioidomycosis of < 8 weeks’ duration and performed a one-time procalcitonin assay, with a cutoff of < 0.25 μg/L indicating a nonbacterial infection. Measurements and Main Results Nineteen of 20 patients (95%) had serum procalcitonin of < 0.25 μg/L. The median procalcitonin level was 0.05 μg/L (range, < 0.05–0.87 μg/L; interquartile range, 0.05–0.05 μg/L). Sixteen of 20 patients (80%) had undetectable procalcitonin of < 0.05 μg/L. The four patients with detectable procalcitonin had a median value of 0.2 μg/L (range, 0.09–0.87 μg/L). Conclusions In this pilot study, procalcitonin was not elevated in immunocompetent patients with primary pulmonary coccidioidomycosis at a median of 32 days after symptom onset. Larger prospective studies are needed to confirm this finding.
Macrophages in diabetic gastroparesis – the missing link?
Neshatian, Leila , Gibbons, Simon J. , Farrugia, Gianrico , Gibbons, S J , Neshatian, Leila

Neurogastroenterology & Motility | August 28, 2014 | Volume: 27 | Issue: 1 | Pages: 7-18

10.1111/nmo.12418 | PMID 25168158 Get It

Abstract Background Diabetic gastroparesis results in significant morbidity for patients and major economic burden for society. Treatment options for diabetic gastroparesis are currently directed at symptom control rather than the underlying disease and are limited. The pathophysiology of diabetic gastroparesis includes damage to intrinsic and extrinsic neurons, smooth muscle, and interstitial cells of C ajal ( ICC ). Oxidative damage in diabetes appears to be one of the primary insults involved in the pathogenesis of several complications of diabetes, including gastroparesis. Recent studies have highlighted the potential role of macrophages as key cellular elements in the pathogenesis of diabetic gastroparesis. Macrophages are important for both homeostasis and defense against a variety of pathogens. Heme oxygenase 1 ( HO 1), an enzyme expressed in a subset of macrophages has emerged as a major protective mechanism against oxidative stress. Activation of macrophages with high levels of HO 1 expression protects against development of delayed gastric emptying in animal models of diabetes, while activation of macrophages that do not express HO 1 are linked to neuromuscular cell injury. Targeting macrophages and HO 1 may therefore be a therapeutic option in diabetic gastroparesis. Purpose This report briefly reviews the pathophysiology of diabetic gastroparesis with a focus on oxidative damage and how activation and polarization of different subtypes of macrophages in the muscularis propria determines development of delay in gastric emptying or protects against its development.
Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi
Aksamit, Timothy R. , Chotirmall, Sanjay H. , Elborn, J.S. , Ranganathan, Sarath , Waters, Valerie , Ratjen, Félix , Chmiel, James F. , Dasenbrook, Elliott C. , LiPuma, John J. , Ratjen, Felix

Annals of the American Thoracic Society | August 28, 2014 | Volume: 11 | Issue: 8 | Pages: 1298-1306

10.1513/annalsats.201405-203as | PMID 25167882 Get It

Abstract Airway infections are a key component of cystic fibrosis (CF) lung disease. Whereas the approach to common pathogens such as Pseudomonas aeruginosa is guided by a significant body of evidence, other infections often pose a considerable challenge to treating physicians. In Part I of this series on the antibiotic management of difficult lung infections, we discussed bacterial organisms including methicillin-resistant Staphylococcus aureus, gram-negative bacterial infections, and treatment of multiple bacterial pathogens. Here, we summarize the approach to infections with nontuberculous mycobacteria, anaerobic bacteria, and fungi. Nontuberculous mycobacteria can significantly impact the course of lung disease in patients with CF, but differentiation between colonization and infection is difficult clinically as coinfection with other micro-organisms is common. Treatment consists of different classes of antibiotics, varies in intensity, and is best guided by a team of specialized clinicians and microbiologists. The ability of anaerobic bacteria to contribute to CF lung disease is less clear, even though clinical relevance has been reported in individual patients. Anaerobes detected in CF sputum are often resistant to multiple drugs, and treatment has not yet been shown to positively affect patient outcome. Fungi have gained significant interest as potential CF pathogens. Although the role of Candida is largely unclear, there is mounting evidence that Scedosporium species and Aspergillus fumigatus, beyond the classical presentation of allergic bronchopulmonary aspergillosis, can be relevant in patients with CF and treatment should be considered. At present, however there remains limited information on how best to select patients who could benefit from antifungal therapy.
A Quality Improvement Project Sustainably Decreased Time to Onset of Active Physical Therapy Intervention in Patients with Acute Lung Injury
Dinglas, Victor D. , Parker, Ann M. , Reddy, Dereddi Raja , Zanni, Jennifer M., Nelliot, Archana, Ciesla, Nancy, Needham, Dale M. , Colantuoni, Elizabeth , Turnbull, Alison E.

Annals of the American Thoracic Society | August 28, 2014 | Volume: 11 | Issue: 8 | Pages: 1230-1238

10.1513/annalsats.201406-231oc | PMID 25167767 Get It

Abstract Rationale Rehabilitation started early during an intensive care unit (ICU) stay is associated with improved outcomes and is the basis for many quality improvement (QI) projects showing important changes in practice. However, little evidence exists regarding whether such changes are sustainable in real-world practice. Objectives To evaluate the sustained effect of a quality improvement project on the timing of initiation of active physical therapy intervention in patients with acute lung injury (ALI). Methods This was a pre–post evaluation using prospectively collected data involving consecutive patients with ALI admitted pre–quality improvement (October 2004–April 2007, n = 120) versus post–quality improvement (July 2009–July 2012, n = 123) from a single medical ICU. Measurements and Main Results The primary outcome was time to first active physical therapy intervention, defined as strengthening, mobility, or cycle ergometry exercises. Among ICU survivors, more patients in the post–quality improvement versus pre–quality improvement group received physical therapy in the ICU (89% vs. 24%, P < 0.001) and were able to stand, transfer, or ambulate during physical therapy in the ICU (64% vs. 7%, P < 0.001). Among all patients in the post–quality improvement versus pre–quality improvement group, there was a shorter median (interquartile range) time to first physical therapy (4 [2, 6] vs. 11 d [6, 29], P < 0.001) and a greater median (interquartile range) proportion of ICU days with physical therapy after initiation (50% [33, 67%] vs. 18% [4, 47%], P = 0.003). In multivariable regression analysis, the post–quality improvement period was associated with shorter time to physical therapy (adjusted hazard ratio [95% confidence interval], 8.38 [4.98, 14.11], P < 0.001), with this association significant for each of the 5 years during the post–quality improvement period. The following variables were independently associated with a longer time to physical therapy: higher Sequential Organ Failure Assessment score (0.93 [0.89, 0.97]), higher Fi O2 (0.86 [0.75, 0.99] for each 10% increase), use of an opioid infusion (0.47 [0.25, 0.89]), and deep sedation (0.24 [0.12, 0.46]). Conclusions In this single-site, pre–post analysis of patients with ALI, an early rehabilitation quality improvement project was independently associated with a substantial decrease in the time to initiation of active physical therapy intervention that was sustained over 5 years. Over the entire pre–post period, severity of illness and sedation were independently associated with a longer time to initiation of active physical therapy intervention in the ICU.
Perceptions of Video-Based Appointments from the Patient's Home: A Patient Survey
Gardner, Matthew R., Jenkins, Sarah M. , O’Neil, Daniel A. , Wood, Douglas L. , Spurrier, Barbara R., Pruthi, Sandhya

Telemedicine and e-Health | August 28, 2014 | Volume: 21 | Issue: 4 | Pages: 281-285

10.1089/tmj.2014.0037 | PMID 25166260 Get It

Background: We examined patient interest in a telehealth model in which the patient supplies the hardware and Internet connectivity to meet with a healthcare provider from his or her home via video call (video appointment). We hoped to understand prospectively the desirability, feasibility, and viability from the patient perspective. Materials and Methods: A phone survey was conducted of a random sample of patients who had been seen in the outpatient setting at a single institution. The sample was stratified by proximity to the local institution with oversampling for patients living outside a 120-mile radius. Results: Out of 500 total patients, 301 patients responded, and 263 met the inclusion criteria. Of those 263 respondents, 38% indicated “very likely” to accept an invitation to see their provider via video, 28.1% “somewhat likely,” and 33.8% “not at all likely.” Of respondents, 75% have broadband, although only 36% reported having a Web camera. The primary factors affecting willingness to participate in a video appointment include comfort in setting up a video call, age, and distance participants would have traveled for an in-clinic appointment. Conclusions: Patient survey data indicate that most patients are likely to be accepting of telehealth care to the home using video call and that most have the required technology. Nevertheless, there are still significant hurdles to effectively implement this adaptation of telehealth care as part of mainstream practice.
Trigger Point Injections for Headache Disorders: Expert Consensus Methodology and Narrative Review
Kuruvilla, Deena E. , Blumenfeld, Andrew , Sorrell, Michael R., Robertson, Carrie E. , Grosberg, Brian M. , Bender, Steven D. , Napchan, Uri, Robbins, Matthew S. , Charleston, Larry , Ashkenazi, Avi , Robertson, Carrie E

Headache: The Journal of Head and Face Pain | August 28, 2014 | Volume: 54 | Issue: 9 | Pages: 1441-1459

10.1111/head.12442 | PMID 25168295 Get It

Objective/Background To review the existing literature and describe a standardized methodology by expert consensus for the performance of trigger point injections ( TPIs ) in the treatment of headache disorders. Despite their widespread use, the efficacy, safety, and methodology of TPIs have not been reviewed specifically for headache disorders by expert consensus. Methods The Peripheral Nerve Blocks and Other Interventional Procedures Special Interest Section of the A merican H eadache S ociety over a series of meetings reached a consensus for nomenclature, indications, contraindications, precautions, procedural details, outcomes, and adverse effects for the use of TPIs for headache disorders. A subcommittee of the Section also reviewed the literature. Results Indications for TPIs may include many types of episodic and chronic primary and secondary headache disorders, with the presence of active trigger points ( TPs ) on physical examination. Contraindications may include infection, a local open skull defect, or an anesthetic allergy, and precautions are necessary in the setting of anticoagulant use, pregnancy, and obesity with unclear anatomical landmarks. The most common muscles selected for TPIs include the trapezius, sternocleidomastoid, and temporalis, with bupivacaine and lidocaine the agents used most frequently. Adverse effects are typically mild with careful patient and procedural selection, though pneumothorax and other serious adverse events have been infrequently reported. Conclusions When performed in the appropriate setting and with the proper expertise, TPIs seem to have a role in the adjunctive treatment of the most common headache disorders. We hope our effort to characterize the methodology of TPIs by expert opinion in the context of published data motivates the performance of evidence‐based and standardized treatment protocols.
A Case Report of Hemicrania Continua‐Like Headache Due to Ipsilateral Inflammatory Orbital Pseudotumor
DeLange, Justin M., Robertson, Carrie E. , Krecke, Karl N. , Garza, Ivan , Robertson, Carrie E

Headache: The Journal of Head and Face Pain | August 28, 2014 | Volume: 54 | Issue: 9 | Pages: 1541-1542

10.1111/head.12440 | PMID 25168202 Get It

The influence of nerve conduits diameter in motor nerve recovery after segmental nerve repair
Giusti, Guilherme , Shin, Richard H., Mattar, Tiago G., Shin, Alexander Y. , Lee, Joo‐Yup , Mattar, Tiago Guedes da Motta , Bishop, Allen T. , Shin, Alexander Y

Microsurgery | August 28, 2014 | Volume: 34 | Issue: 8 | Pages: 646-652

10.1002/micr.22312 | PMID 25163597 Get It

Sequencing of Charcot–Marie–Tooth disease genes in a toxic polyneuropathy
Beutler, Andreas S. , Kulkarni, Amit , Kanwar, Rahul , Klein, Christopher J. , Therneau, Terry M. , Qin, Rui , Banck, Michaela S., Boora, Ganesh K., Ruddy, Kathryn J. , Smalley, Regenia L., Cunningham, Julie M. , Le‐Lindqwister, Nguyet, Beyerlein, Peter, Schroth, Gary P. , Windebank, Anthony J. , Züchner, Stephan , Loprinzi, Charles L. , Wu, Yanhong , Klein, Christopher J

Annals of Neurology | August 28, 2014 | Volume: 76 | Issue: 5 | Pages: 727-737

10.1002/ana.24265 | PMID 25164601 Get It

ObjectiveMutations in Charcot–Marie–Tooth disease (CMT) genes are the cause of rare familial forms of polyneuropathy. Whether allelic variability in CMT genes is also associated with common forms of polyneuropathy—considered “acquired” in medical parlance—is unknown. Chemotherapy‐induced peripheral neuropathy (CIPN) occurs commonly in cancer patients and is individually unpredictable. We used CIPN as a clinical model to investigate the association of non‐CMT polyneuropathy with CMT genes.MethodsA total of 269 neurologically asymptomatic cancer patients were enrolled in the clinical trial Alliance N08C1 to receive the neurotoxic drug paclitaxel, while undergoing prospective assessments for polyneuropathy. Forty‐nine CMT genes were analyzed by targeted massively parallel sequencing of genomic DNA from patient blood.ResultsA total of 119 (of 269) patients were identified from the 2 ends of the polyneuropathy phenotype distribution: patients that were most and least susceptible to paclitaxel polyneuropathy. The CMT gene PRX was found to be deleteriously mutated in patients who were susceptible to CIPN but not in controls (p = 8 × 10−3). Genetic variation in another CMT gene, ARHGEF10, was highly significantly associated with CIPN (p = 5 × 10−4). Three nonsynonymous recurrent single nucleotide variants contributed to the ARHGEF10 signal: rs9657362, rs2294039, and rs17683288. Of these, rs9657362 had the strongest effect (odds ratio = 4.8, p = 4 × 10−4).InterpretationThe results reveal an association of CMT gene allelic variability with susceptibility to CIPN. The findings raise the possibility that other acquired polyneuropathies may also be codetermined by genetic etiological factors, of which some may be related to genes already known to cause the phenotypically related Mendelian disorders of CMT. Ann Neurol 2014;76:727–737